Indeed, a transcriptomics study [57] analyzing melanoma patient tumor biopsies before and after treatments with BRAF inhibitors Dabrafenib and Vemurafenib revealed that RIPK3 expression was increased by at least 1.2-fold in 58.3% of the patients and decreased by least 1.2-fold in 25% of the patients, while no change was observed in 16.7% of the patients, consistent with the heterogeneous nature of RIPK3 expression loss (Fig 4D). The gene discussed is RIPK3; the disease is melanoma.